Berberine (sulfate)

Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

[1]Cai Y, et al. Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. J Nat Med. 2014 Jan;68 (1) :53-62.|[2]Cui HX, et al. Preparation and Evaluation of Antidiabetic Agents of Berberine Organic Acid Salts for Enhancing the Bioavailability. Molecules. 2018 Dec 28;24 (1) :103.|[3]Boberek JM, et al., Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS One. 2010 Oct 29;5 (10) :e13745. |[4]Remppis A, et al., Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway. Mediators Inflamm. 2010;2010:194896.|[5]Bae J, et al., Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1. Mol Cells. 2013 Feb;35 (2) :151-7. |[6]Ye Y, et al., Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol. 2021 Apr 26;12:653887.

Int Immunopharmacol. 2024 May 30:133:112036.|Mol Reprod Dev. 2024 Aug;91 (8) :e23768.|NPJ Sci Food. 2025 Feb 4;9 (1) :16.|Acta Pharm Sin B. 2025 Jul 9.|Aquacult Nutr. 14 Jul 2022.|Biochem Pharmacol. 2021 Jun:188:114576.|Biochim Biophys Acta Mol Basis Dis. 2025 May 22:167920.|Cell Signal. 2025 Jul:131:111732.|Chin Med. 2025 Nov 17;20 (1) :190.|CNS Neurosci Ther. 2025 Feb;31 (2) :e70253.|Front Pharmacol. 2023 Apr 18:14:1148611.|Inflammopharmacology. 2024 May 17.|Int Immunopharmacol. 2024 May 29:136:112278.|Int Immunopharmacol. 2024 Sep 24;142 (Pt B) :113227.|Int J Biol Macromol. 2025 May 21:144496.|J Appl Toxicol. 2024 Nov;44 (11) :1700-1713.|J Food Biochem. 2025 Jul 16.|Mech Ageing Dev. 2020 Oct;191:111347.|Molecules. 2024 May 14.|Nat Commun. 2025 Jan 2;16 (1) :212.|Oncologie. 2023 Mar 10.|Phytomedicine. 2023 Sep:118:154962.|Phytomedicine. 2025 Apr:139:156517.|Research Square Preprint. 2021 May.|Research Square Print. 2022 Aug.|Acta Pharmacol Sin. 2023 Feb;44 (2) :332-344.|Appl Biochem Biotechnol. 2024 Aug;196 (8) :5265-5282.|Aquaculture. 15 May 2022, 738055.|Biol Pharm Bull. 2022 Oct 1;45 (10) :1444-1451.|Biomed Pharmacother. 2024 Jan:170:116012.|BMC Pharmacol Toxicol. 2023 May 11;24 (1) :29.|Cell Stem Cell. 2025 May 1;32 (5) :778-794.e10.|Evid Based Complement Alternat Med. 2021 May 4:2021:6688629.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Exp Cell Res. 2024 May 13:114094.|Fish Shellfish Immunol. 2024 Jun:149:109522.|Food Chem Toxicol. 2023 May:175:113743.|Gene. 2022 Mar 30:816:146171.|Genome Instab Dis. 2025 Mar.|Hepatol Commun. 2024 Mar 29;8 (4) :e0405.|Int J Nanomedicine. 2023 Jul 31:18:4347-4363.|J Bone Miner Metab. 2021 Sep;39 (5) :748-756.|J Cell Mol Med. 2025 Sep;29 (17) :e70836.|J Ethnopharmacol. 2022 Mar 1:285:114786.|J Ethnopharmacol. 2024 Apr 24:324:117829.|J Inflamm Res. 2025 Aug 21:18:11451-11461.|J Pharm Pharmacol. 2022 Sep 1;74 (9) :1353-1363.|JCI Insight. 2023 Jul 24;8 (14) :e166306.|Microb Pathog. 2025 Dec:209:108114.|Mol Med Rep. 2023 Jan;27 (1) :17.|Mol Med. 2024 Dec 20;30 (1) :251.|Pharm Biol. 2024 Dec;62 (1) :53-61.|Phytomedicine. 2024 Jan:123:155247.|Phytomedicine. 2025 Sep 4:148:157233.|Res Sq. 2025 Apr 15.|Research Square Preprint. 2021 Jun.|Research Square Preprint. 2021 Sep.|Sci Rep. 2022 Oct 17;12 (1) :17350.|Sci Rep. 2025 Jul 1;15 (1) :21623.|SSRN. 2023 Jan 27.|Toxicol Appl Pharmacol. 2025 Sep 13:505:117563.|Toxicol In Vitro. 2025 Dec:109:106128.|Phytomedicine. 2024 Dec:135:156111.